From GlobeNewswire: 2025-06-09 19:30:00

Ascentage Pharma will present 13 studies at the 2025 European Hematology Association Annual Congress in Milan, including research on olverembatinib, lisaftoclax, and APG-5918. The studies cover various treatments for leukemia, lymphoma, and myeloid/lymphoid neoplasms. The company aims to address unmet medical needs in cancer treatment with innovative drug candidates targeting key proteins. Olverembatinib, a third-generation BCR-ABL1 inhibitor, is approved in China for CML treatment and is in global Phase III trials. Lisaftoclax, a Bcl-2 inhibitor, is also in clinical trials for various hematologic malignancies. Ascentage Pharma collaborates with leading biotech and pharmaceutical companies and research institutions to advance cancer research and treatment.



Read more at GlobeNewswire: Thirteen Studies of Ascentage Pharma’s Assets Including